Evaluating the Effect of Underlying Pulmonary Disease on the Clinical Outcome and survival among Patients with COVID-19: Using Propensity Score Matching

Coronavirus (Covid-19) is a life-threatening factor throughout the world. Having an underlying disease among the patients with this disease diminishes the clinical effectiveness and increases their mortality rate. Hence, the study was carried out to compare the clinical outcomes in patients with COVID-19 with and without pulmonary disease using propensity score matching. This case-control study was conducted on 299 COVID-19 patients with pulmonary disease (case group) and 299 COVID-19 patients without pulmonary diseases (control group). Matching the patients in the case and control groups was done using propensity score matching. Logistic regression was used to assess the effect of factors on the patient's clinical outcome (recovery-death), and the Cox model was used to determine the factors affecting patient survival. Data were analyzed in R software. The mean (SD) of the patients' age in the case and control groups was 65.49 (15.55) and 65.67 (15.55), respectively. The results of the logistic regression model showed that age, pulmonary disease, nausea, and blood oxygen affect patient death. The results of the Cox proportional-hazards model indicated that the variables of age, blood oxygen, and pulmonary had a significant effect on patient survival. Given the high mortality rate among patients with COVID-19 and chronic pulmonary disease, these patients are considered a high-risk group and need special care.

[1]  N. Motoc,et al.  Prognosis Predictive Markers in Patients with Chronic Obstructive Pulmonary Disease and COVID-19 , 2023, Diagnostics.

[2]  Nikhil T. Awatade,et al.  The Complex Association between COPD and COVID-19 , 2023, Journal of clinical medicine.

[3]  G. Guaraldi,et al.  Drug treatment of COVID-19 infection , 2023, Current opinion in pulmonary medicine.

[4]  M. Falcone,et al.  Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience , 2022, Infectious Diseases and Therapy.

[5]  R. Flisiak,et al.  Oral antiviral treatments for COVID-19: opportunities and challenges , 2022, Pharmacological Reports.

[6]  C. Schooling,et al.  Association of smoking, lung function and COPD in COVID‐19 risk: a two‐step Mendelian randomization study , 2022, Addiction.

[7]  J. Butterton,et al.  Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients , 2021, The New England journal of medicine.

[8]  G. Roshanaei,et al.  The effect of underlying diabetes disease on clinical outcome and survival in patients with Covid-19: a propensity score matching study , 2021, Journal of Diabetes & Metabolic Disorders.

[9]  W. Guan,et al.  Impact of Chronic Respiratory Diseases on the Outcomes of COVID-19 , 2021, Archivos de Bronconeumología.

[10]  P. Koul,et al.  The impact of COVID-19 on patients with preexisting interstitial lung disease: High mortality in these high-risk patients , 2021, Lung India : official organ of Indian Chest Society.

[11]  D. Neuberg,et al.  Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis , 2021, American journal of hematology.

[12]  Yu Wang,et al.  Risk factors of mortality and contribution of treatment in patients infected with COVID-19: a retrospective propensity score matched study , 2020, Current medical research and opinion.

[13]  B. Morrison,et al.  Endothelial Cell Contributions to COVID-19 , 2020, Pathogens.

[14]  S. El-Chemaly,et al.  Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case–Control Study , 2020, American journal of respiratory and critical care medicine.

[15]  P. Peng,et al.  Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2 , 2020, European Respiratory Journal.

[16]  Sang Woo Park,et al.  Potential Role of Social Distancing in Mitigating Spread of Coronavirus Disease, South Korea , 2020, Emerging infectious diseases.

[17]  Jordan J. Clark,et al.  Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score , 2020, BMJ.

[18]  D. Ma,et al.  Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis , 2020, Journal of Hematology & Oncology.

[19]  Jiaofeng Huang,et al.  The impact of COPD and smoking history on the severity of COVID‐19: A systemic review and meta‐analysis , 2020, Journal of medical virology.

[20]  Jing Shi,et al.  Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan , 2020, Journal of Allergy and Clinical Immunology.

[21]  A. Desai,et al.  COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis. , 2020, JCO global oncology.

[22]  C. Wang,et al.  Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China , 2020, Annals of Oncology.

[23]  W. Gong,et al.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.

[24]  G. Lippi,et al.  Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19) , 2020, Respiratory Medicine.

[25]  G. Onder,et al.  Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. , 2020, JAMA.

[26]  Lei Dong,et al.  Kidney disease is associated with in-hospital death of patients with COVID-19 , 2020, Kidney International.

[27]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[28]  Rui Ji,et al.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[29]  Wei Wang,et al.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.

[30]  C. Akdis,et al.  Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China , 2020, Allergy.

[31]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[32]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[33]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[34]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[35]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[36]  J. Ryu,et al.  The Role of Infection in Interstitial Lung Diseases , 2017, Chest.

[37]  D. Weiskopf,et al.  The aging of the immune system , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[38]  中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组 The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China./ 新型冠状病毒肺炎流行病学特征分析 , 2020 .